The landscape of pulmonary embolism (PE) management is undergoing a significant shift as new clinical data underscores the vital importance of "time-to-treatment." A recent post-hoc analysis of the SYMPHONY-PE trial, published in Circulation: Cardiovascular Interventions, has provided compelling evidence that early mechanical thrombectomy—defined as intervention within 12 hours of diagnostic imaging—yields superior outcomes for patients suffering from intermediate-risk pulmonary embolism.
As medical technology advances, the ability to intervene rapidly is becoming a cornerstone of cardiovascular care. Imperative Care, the manufacturer of the Symphony thrombectomy system, has reported that patients treated within the 12-hour window experienced more pronounced improvements in right ventricular (RV) function and pulmonary artery pressure compared to those who received delayed treatment.
Main Facts: The 12-Hour Threshold
Pulmonary embolism, a blockage in one of the pulmonary arteries in the lungs, remains a leading cause of mortality in hospitalized patients. While traditional treatments often involve anticoagulation, mechanical thrombectomy—the physical removal of blood clots—has emerged as a powerful tool for intermediate-risk patients who face significant hemodynamic stress but have not yet progressed to full cardiogenic shock.
The analysis of the SYMPHONY-PE trial focused on 109 participants. Researchers categorized these patients into two distinct cohorts: those who underwent the thrombectomy procedure within 12 hours of their initial diagnostic imaging, and those who received the intervention after this threshold.
Of the total cohort, 48 patients (approximately 44%) received "early" treatment. The findings suggest that this cohort benefited from a more rapid reduction in physiological strain on the heart, particularly the right ventricle, which is tasked with pumping blood against the resistance created by the blockage.
Chronology of Clinical Progress
The journey to these findings represents a multi-year effort by Imperative Care to refine the standards of PE intervention. The chronology of this progress highlights a deliberate, data-driven approach:
- August 2025: The Symphony thrombectomy system receives formal clearance from the US Food and Drug Administration (FDA). This clearance was underpinned by a robust multi-site Investigational Device Exemption (IDE) study, which provided the foundational clinical evidence for the device’s efficacy and safety.
- March 2026: Building on the momentum of the commercial launch, Imperative Care initiates the CLEAR-IT study. This prospective, observational trial is designed to evaluate the real-world performance of both the Symphony and Prodigy thrombectomy systems, signaling a move toward broader clinical evidence collection.
- June 2026: The release of the post-hoc analysis in Circulation: Cardiovascular Interventions. This report marks a pivotal moment, as it shifts the focus from mere device safety to the optimization of clinical workflow—specifically, the "golden hour" concept applied to PE treatment.
Supporting Data: Hemodynamic Improvement
The statistical data provided by the analysis offers a clear picture of why early intervention is advantageous. The primary metrics for success in these patients are pulmonary artery pressure and the RV/LV ratio—a measure of the size and strain of the right ventricle relative to the left.
Pulmonary Artery Pressure Reduction
The analysis revealed that patients treated within 12 hours saw an average reduction in pulmonary artery pressure of 8.6 units. In contrast, those treated after the 12-hour mark saw a reduction of only 5.8 units. The researchers noted that this 2.8-point differential reached nominal statistical significance, suggesting that the faster a clinician can relieve the obstruction, the more effectively the heart can return to its normal hemodynamic state.
RV/LV Ratio Improvement
The right ventricle-to-left ventricle ratio is a critical prognostic indicator. Patients in the early intervention group showed a reduction of 0.52 in their RV/LV ratio from baseline to 48 hours. The late intervention group showed a more modest reduction of 0.37.
Perhaps most significantly, the data indicated that these benefits were not uniform across all patients; the efficacy of early intervention was most pronounced in higher-risk cases, as determined by the composite pulmonary embolism shock score (CPES). This suggests that for patients already showing signs of physiological instability, the "time is muscle" philosophy—long associated with heart attacks—should also be applied to pulmonary embolism.
Safety Profile
Crucially, the pursuit of speed did not come at the cost of patient safety. The analysis found no significant difference in major adverse events (MAEs) between the two groups within the 48-hour post-procedure window. Only one MAE was reported in the early group, while zero were reported in the late group—a statistical variance that the study authors did not deem significant. Furthermore, there were no device-related serious adverse events or deaths recorded in either group, reinforcing the safety profile of the Symphony system.
Official Responses and Strategic Vision
The leadership at Imperative Care has framed these results as a validation of their core philosophy: removing the complexity of thrombectomy to allow for more efficient patient care.
Fred Khosravi, Chairman and CEO of Imperative Care, emphasized the impact on clinical decision-making. "We set out to establish a new standard in PE treatment by developing a large-bore system that removes the guesswork from thrombectomy," Khosravi stated. "It is designed to enable more efficient procedures and real-time decision-making so physicians can focus on what matters most: the patient."
Khosravi also highlighted the rapid adoption of the technology, noting that over 500 patients have been treated with the Symphony system since its commercial launch. "We are encouraged by the growing physician confidence in Symphony and the continued clinical evidence supporting its procedural efficiency and favourable safety profile," he added.
Implications for Future Practice
The implications of these findings are far-reaching for interventional cardiologists, pulmonologists, and emergency medicine departments.
1. Standardization of "Fast-Track" PE Protocols
The data suggests that hospitals should strive to integrate mechanical thrombectomy into their "code" protocols for PE. Much like stroke or myocardial infarction, the 12-hour window appears to be a critical threshold. If these results are replicated in larger prospective studies, they could lead to updated clinical guidelines that prioritize early mechanical intervention over prolonged attempts at medical management for intermediate-risk patients.
2. Refining Patient Selection via CPES
The finding that higher-risk patients (as measured by CPES) benefit most from early intervention provides clinicians with a clearer decision-making framework. Future triage protocols may use the CPES score to "fast-track" specific patients directly to the cath lab, bypassing unnecessary delays in the ICU or emergency department.
3. The Economic Argument
While the current analysis focuses on clinical outcomes, the implications for hospital economics are clear. Faster, more efficient procedures that result in improved patient outcomes and shorter hospital stays generally correlate with lower overall costs of care. By demonstrating that the Symphony system enables safe, rapid procedures, Imperative Care is positioning its technology as a solution that serves both the clinical and financial interests of healthcare institutions.
4. Future Research Directions
The ongoing CLEAR-IT study will be essential in confirming these retrospective observations. As Imperative Care continues to gather data on both the Symphony and Prodigy systems, the medical community will be watching to see if the "12-hour rule" becomes a standard performance metric for PE treatment centers worldwide.
Conclusion
The latest data from the SYMPHONY-PE trial serves as a clarion call for the rapid management of pulmonary embolism. By identifying that early mechanical thrombectomy provides superior hemodynamic relief without increasing the risk of adverse events, Imperative Care has provided a significant contribution to the evolving standards of cardiovascular care. As hospitals continue to refine their approach to PE, the integration of high-efficiency thrombectomy systems and a commitment to rapid intervention will likely become the benchmark for quality care, ultimately saving lives and improving long-term recovery for patients worldwide.
About the Author
